Neisseria meningitidis

From WikiProjectMed
Jump to navigation Jump to search

Neisseria meningitidis
Scanning electron micrograph of a single "N. meningitidis" cell (colorized in blue) with its adhesive pili (colorized in yellow). The scale bar corresponds to 1 µm.
Scanning electron micrograph of a single N. meningitidis cell (colorized in blue) with its adhesive pili (colorized in yellow). The scale bar corresponds to 1 µm.
Scientific classification edit
Domain: Bacteria
Phylum: Pseudomonadota
Class: Betaproteobacteria
Order: Neisseriales
Family: Neisseriaceae
Genus: Neisseria
N. meningitidis
Binomial name
Neisseria meningitidis
Albrecht & Ghon 1901

Neisseria meningitidis, often referred to as meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis.[1] The bacterium is referred to as a coccus because it is round, and more specifically a diplococcus because of its tendency to form pairs.

About 10% of adults are carriers of the bacteria in their nasopharynx.[2] As an exclusively human pathogen, it is the main cause of bacterial meningitis in children and young adults, causing developmental impairment and death in about 10% of cases. It causes the only form of bacterial meningitis known to occur epidemically, mainly in Africa and Asia. It occurs worldwide in both epidemic and endemic form.[3]

N. meningitidis is spread through saliva and respiratory secretions during coughing, sneezing, kissing, chewing on toys and even through sharing a source of fresh water. It has also been reported to be transmitted through oral sex and cause urethritis in men.[4] It infects its host cells by sticking to them with long thin extensions called pili and the surface-exposed proteins Opa and Opc and has several virulence factors.


This illustration depicted a three-dimensional (3D), computer-generated image, of a number of diplococcal, Gram-negative, Neisseria meningitidis, bacteria. The artistic recreation was based upon scanning electron microscopic (SEM) imagery.

N. meningitidis is a Gram-negative diplococcus since it has an outer and inner membranes with a thin layer of peptidoglycan in between. It is 0.6–1.0 micrometers in size. It tests positive for the enzyme cytochrome c oxidase.[5]


N. meningitidis is a part of the normal nonpathogenic flora in the nasopharynx of up to 8–25% of adults.[6] It colonizes and infects only humans, and has never been isolated from other animals. This is thought to stem from the bacterium's inability to get iron from sources other than human transferrin and lactoferrin.[7]


Disease-causing strains are classified according to the antigenic structure of their polysaccharide capsule.[8] Serotype distribution varies markedly around the world.[6] Among the 13 identified capsular types of N. meningitidis, six (A, B, C, W135, X, and Y) account for most disease cases worldwide.[9] Type A has been the most prevalent in Africa and Asia, but is rare/practically absent in North America. In the United States, serogroup B is the predominant cause of disease and mortality, followed by serogroup C. The multiple subtypes have hindered development of a universal vaccine for meningococcal disease.



Lipooligosaccharide (LOS) is a component of the outer membrane of N. meningitidis. This acts as an endotoxin and is responsible for septic shock and hemorrhage due to the destruction of red blood cells.[10] Other virulence factors include a polysaccharide capsule which prevents host phagocytosis and aids in evasion of the host immune response; fimbriae mediate attachment of the bacterium to the epithelial cells of the nasopharynx.[11][12] It infects the cell by sticking to it mainly with long thin extensions called pili and the surface-exposed proteins Opa and Opc.[13] Meningococci produce an IgA protease, an enzyme that cleaves IgA class antibodies and thus allows the bacteria to evade a subclass of the humoral immune system.

A hypervirulent strain was discovered in China. Its impact is yet to be determined.[14]

Complement inhibition

Factor H binding protein (fHbp) that is exhibited in N. meningitidis and some commensal species is the main inhibitor of the alternative complement pathway. fHbp protects meningococci from complement-mediated death in human serum experiments, but has also been shown to protect meningococci from antimicrobial peptides in vitro. Factor H binding protein is key to the pathogenesis of N. meningitidis, and is, therefore, important as a potential vaccine candidate.[15] Porins are also an important factor for complement inhibition for both pathogenic and commensal species. Porins are important for nutrient acquisition. Porins are also recognized by TLR2, they bind complement factors (C3b, C4b, factor H, and C4bp (complement factor 4b-binding protein)). Cooperation with pili for CR3-mediated internalization is another function of porins. Ability to translocate into host cells and modulate reactive oxygen species production and apoptosis is made possible by porins, as well. Strains of the same species can express different porins.


At least 8 complete genomes of Neisseria meningitidis strains have been determined which encode about 2,100 to 2,500 proteins.[16]

The genome of strain MC58 (serogroup B) has 2,272,351-base pairs. When sequenced in 2000, it was found to contain 2158 open reading frames (ORFs). Of these, a biological function was predicted for 1158 (53.7%). There were three major islands of horizontal DNA transfer found. Two encode proteins involved in pathogenicity. The third island only codes for hypothetical proteins. They also found more genes that undergo phase variation than any pathogen then known. Phase variation is a mechanism that helps the pathogen to evade the immune system of the host.[17]

The genome size of strain H44/76 is 2.18 Mb, and encodes 2,480 open reading frames (ORFs), compared to 2.27 Mb and 2,465 ORFs for MC58.[16] Both strains have a GC content of 51.5%.[16] A comparison with MC58 showed that four genes are uniquely present in H44/76 and nine genes are only present in MC58. Of all ORFs in H44/76, 2,317 (93%) show more than 99% sequence identity.[16]

The complete genome sequence of strain NMA510612 (serogroup A) consists of one circular chromosome with a size of 2,188,020 bp, and the average GC content is 51.5%. The chromosome is predicted to possess 4 rRNA operons, 163 insertion elements (IS), 59 tRNAs, and 2,462 ORFs.[18]

Genetic transformation

Genetic transformation is the process by which a recipient bacterial cell takes up DNA from a neighboring cell and integrates this DNA into the recipient's genome by recombination. In N. meningitidis, DNA transformation requires the presence of short DNA sequences (9–10 mers residing in coding regions) of the donor DNA. These sequences are called DNA uptake sequences (DUSs). Specific recognition of these sequences is mediated by a type IV pilin.[19] In N. meningitidis DUSs occur at a significantly higher density in genes involved in DNA repair and recombination (as well as in restriction-modification and replication) than in other annotated gene groups. The over-representation of DUS in DNA repair and recombination genes may reflect the benefit of maintaining the integrity of the DNA repair and recombination machinery by preferentially taking up genome maintenance genes, that could replace their damaged counterparts in the recipient cell.[20]

N. meningititis colonizes the nasopharyngeal mucosa, which is rich in macrophages. Upon their activation, macrophages produce superoxide (O2) and hydrogen peroxide (H2O2). Thus N. meningitidis is likely to encounter oxidative stress during its life cycle.[21] Consequently, an important benefit of genetic transformation to N. meningitidis may be the maintenance of the recombination and repair machinery of the cell that removes oxidative DNA damages such as those caused by reactive oxygen. This is consistent with the more general idea that transformation benefits bacterial pathogens by facilitating repair of DNA damages produced by the oxidative defenses of the host during infection.[22]



Meningococcus can cause meningitis and other forms of meningococcal disease.[23] It initially produces general symptoms like fatigue, fever, and headache and can rapidly progress to neck stiffness, coma and death in 10% of cases. Petechiae occur in about 50% of cases. Chance of survival is highly correlated with blood cortisol levels, and so a reduction in cortisol can be used to determine likelihood of patient mortality.[24] Symptoms of meningococcal meningitis are easily confused with those caused by other bacteria, such as Haemophilus influenzae and Streptococcus pneumoniae.[7][14] Suspicion of meningitis is a medical emergency and immediate medical assessment is recommended. Current guidance in the United Kingdom is that if a case of meningococcal meningitis or septicaemia (infection of the blood) is suspected, intravenous antibiotics should be given and the ill person admitted to the hospital.[25] This means that laboratory tests may be less likely to confirm the presence of Neisseria meningitidis as the antibiotics will dramatically lower the number of bacteria in the body. The UK guidance is based on the idea that the reduced ability to identify the bacteria is outweighed by reduced chance of death.

Septicaemia caused by Neisseria meningitidis has received much less public attention than meningococcal meningitis even though septicaemia has been linked to infant deaths.[7] Meningococcal septicaemia typically causes a purpuric rash, that does not lose its color when pressed with a glass slide ("non-blanching") and does not cause the classical symptoms of meningitis. This means the condition may be ignored by those not aware of the significance of the rash. Septicaemia carries an approximate 50% mortality rate over a few hours from initial onset.

Other severe complications include Waterhouse–Friderichsen syndrome, a massive, usually bilateral, hemorrhage into the adrenal glands caused by fulminant meningococcemia, adrenal insufficiency, and disseminated intravascular coagulation.[14]

Not all instances of a purpura-like rash are due to meningococcal septicaemia; other possible causes, such as idiopathic thrombocytopenic purpura (ITP; a platelet disorder) and Henoch–Schönlein purpura, also need prompt investigation.


The growth of Neisseria meningitidis colonies on New York City agar
Neisseria meningitidis in cerebrospinal fluid (CSF) seen by Gram stain at 1000x magnification

A small amount of cerebrospinal fluid (CSF) is sent to the laboratory as soon as possible for analysis. The diagnosis is suspected, when Gram-negative diplococci are seen on Gram stain of a centrifuged sample of CSF; sometimes they are located inside white blood cells. The microscopic identification takes around 1–2 hours after specimen arrival in the laboratory.[23]

The gold standard of diagnosis is microbiological isolation of N. meningitidis by growth from a sterile body fluid, which could be CSF or blood.[14] Diagnosis is confirmed when the organism has grown, most often on a chocolate agar plate, but also on Thayer-Martin agar. To differentiate any bacterial growth from other species a small amount of a bacterial colony is tested for oxidase, catalase for which all clinically relevant Neisseria show a positive reaction, and the carbohydrates maltose, sucrose, and glucose, in which N. meningitidis will ferment that is, utilize the glucose and maltose. Finally, serology determines the subgroup of the N. meningitidis, which is important for epidemiological surveillance purposes; this may often only be done in specialized laboratories.

The above tests take a minimum of 48–72 hours turnaround time for growing the organism, and up to a week more for serotyping. Growth can and often does fail, either because antibiotics have been given preemptively, or because specimens have been inappropriately transported, as the organism is extremely susceptible to antibiotics and fastidious in its temperature, CO
and growth medium requirements.

Polymerase chain reaction (PCR) tests where available, mostly in industrialized countries, have been increasingly used; PCR can rapidly identify the organism, and works even after antibiotics have been given.[14]


All recent contacts of the infected patient over the 7 days before onset should receive medication to prevent them from contracting the infection. This especially includes young children and their child caregivers or nursery-school contacts, as well as anyone who had direct exposure to the patient through kissing, sharing utensils, or medical interventions such as mouth-to-mouth resuscitation. Anyone who frequently ate, slept or stayed at the patient's home during the 7 days before the onset of symptom, or those who sat beside the patient on an airplane flight or classroom for 8 hours or longer, should also receive chemoprophylaxis. The agent of choice is usually oral rifampicin for a few days.[14]

Receiving a dose of the Meningococcal vaccine before traveling to a country in the "meningitis belt" or having a booster meningitis vaccine, normally five years apart could prevent someone from getting an infection from the pathogen.[26]


United States

A number of vaccines are available in the U.S. to prevent meningococcal disease. Some of the vaccines cover serogroup B, while others cover A, C, W, and Y.[27] The Centers for Disease Control and Prevention (CDC) recommends all teenagers receive MenACWY vaccine and booster, with optional MenB. MenACWY and MenB are also recommended for people of other ages with various medical conditions and social risk factors.[27]

A meningococcal polysaccharide vaccine (MPSV4) has been available since the 1970s and is the only meningococcal vaccine licensed for people older than 55. MPSV4 may be used in people 2–55 years old if the MCV4 vaccines are not available or contraindicated. Two meningococcal conjugate vaccines (MCV4) are licensed for use in the U.S. The first conjugate vaccine was licensed in 2005, the second in 2010. Conjugate vaccines are the preferred vaccine for people 2 through 55 years of age. It is indicated in those with impaired immunity, such as nephrotic syndrome or splenectomy.

In June 2012, the U.S. Food and Drug Administration (FDA) approved a combination vaccine against two types of meningococcal diseases and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, was designed to prevent disease caused by Neisseria meningitidis serogroups C and Y, and Haemophilus influenzae type b (Hib). It was the first meningococcal vaccine that could be given to infants as young as six weeks old.[28]

In October 2014 the FDA approved the first vaccine effective against serogroup B, named Trumenba, for use in 10- to 25-year-old individuals.[29]


In 2010, the Meningitis Vaccine Project introduced a vaccine called MenAfriVac in the African meningitis belt. It was made by generic drug maker Serum Institute of India and cost 50 U.S. cents per injection. Beginning in Burkina Faso in 2010, it has been given to 215 million people across Benin, Cameroon, Chad, Ivory Coast, Ethiopia, Ghana, Mali, Niger, Mauritania, Nigeria, Senegal, Sudan, Togo and Gambia.[30] The vaccination campaign has resulted in near-elimination of serogroup A meningitis from the participating countries.[31]


Persons with confirmed N. meningitidis infection should be hospitalized immediately for treatment with antibiotics. Because meningococcal disease can disseminate very rapidly, a single dose of intramuscular antibiotic is often given at the earliest possible opportunity, even before hospitalization, if disease symptoms look suspicious enough.[14] Third-generation cephalosporin antibiotics (i.e. cefotaxime, ceftriaxone) should be used to treat a suspected or culture-proven meningococcal infection before antibiotic susceptibility results are available.[32] Clinical practice guidelines endorse empirical treatment in the event a lumbar puncture to collect cerebrospinal fluid (CSF) for laboratory testing cannot first be performed.[32][33] Antibiotic treatment may affect the results of microbiology tests, but a diagnosis may be made on the basis of blood-cultures and clinical examination.[34]


N. meningitidis is a major cause of illness, developmental impairment and death during childhood in industrialized countries and has been responsible for epidemics in Africa and in Asia. Every year, about 2,500 to 3,500 people become infected with N. meningitidis in the US, with a frequency of about 1 in 100,000. Children younger than 5 years are at greatest risk, followed by teenagers of high school age. Rates in the African meningitis belt were as high as 1 in 1,000 to 1 in 100 before introduction of a vaccine in 2010.[14] The incidence of meningococcal disease is highest among infants (children younger than 1-year-old) whose immune system is relatively immature. In industrialized countries there is a second peak of incidence in young adults, who are congregating closely, living in dormitories or smoking.[35] Vaccine development is ongoing.[36]

It is spread through saliva and other respiratory secretions during coughing, sneezing, kissing, and chewing on toys. Inhalation of respiratory droplets from a carrier which may be someone who is themselves in the early stages of disease can transmit the bacteria. Close contact with a carrier is the predominant risk factor. Other risk factors include a weakened general or local immune response, such as a recent upper respiratory infection, smoking, and complement deficiency. The incubation period is short, from 2 to 10 days. In susceptible individuals, N. meningitidis may invade the bloodstream and cause a systemic infection, sepsis, disseminated intravascular coagulation, breakdown of circulation, and septic shock.


In 1884 Ettore Marchiafava and Angelo Celli first observed the bacterium inside cells in the cerebral spinal fluid (CSF).[37] In 1887 Anton Weichselbaum isolated the bacterium from the CSF of patients with bacterial meningitis.[38] He named the bacterium Diplococcus intracellularis meningitidis.[37]


Components from Neisseria meningitidis are being harnessed in biotechnology. Its Cas9 enzyme is a useful tool in CRISPR gene editing because the enzyme is small and has distinct targeting features to the commonly used enzyme from Streptococcus pyogenes.[39] The cell-surface protein FrpC from Neisseria meningitidis has been engineered to allow covalent coupling between proteins, because it generates a reactive anhydride when exposed to calcium.[40] The bacterium also expresses unique enzymes able to cleave IgA antibodies.[41]

See also


  1. Suryadevara, Manika (2021). "19. Meningococcus". In Domachowske, Joseph; Suryadevara, Manika (eds.). Vaccines: A Clinical Overview and Practical Guide. Switzerland: Springer. pp. 235–246. ISBN 978-3-030-58416-0. Archived from the original on 2022-01-11. Retrieved 2022-03-03.
  2. Hitchcock PJ, Robinson Jr EN, McGee ZA, Koomey JM (1993). "Neisseriae: Gonococcus and Meningococcus". In Schaechter M, Medoff G, Eisenstein BI (eds.). Mechanisms of Microbial Disease (2nd ed.). Baltimore: Williams & Wilkins. p. 231. ISBN 9780683076066.
  3. "Meningococcal Disease in Other Countries". National Center for Immunization and Respiratory Diseases. Meningococcal Disease. Centers for Disease Control and Prevention. 31 May 2019. Archived from the original on 2020-10-30.
  4. Bazan JA, Peterson AS, Kirkcaldy RD, Briere EC, Maierhofer C, Turner AN, et al. (June 2016). "Notes from the Field: Increase in Neisseria meningitidis-Associated Urethritis Among Men at Two Sentinel Clinics - Columbus, Ohio, and Oakland County, Michigan, 2015". MMWR. Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. 65 (21): 550–2. doi:10.15585/mmwr.mm6521a5. PMC 5390329. PMID 27254649.
  5. "Neisseria meningitidis". National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Characteristics of N. gonorrhoeae and Related Species. Centers for Disease Control and Prevention. 31 March 2017. Archived from the original on 2020-10-20.
  6. 6.0 6.1 Stephens DS, Greenwood B, Brandtzaeg P (June 2007). "Epidemic meningitis, meningococcaemia, and Neisseria meningitidis". Lancet. 369 (9580): 2196–2210. CiteSeerX doi:10.1016/S0140-6736(07)61016-2. PMID 17604802. S2CID 16951072.
  7. 7.0 7.1 7.2 Pollard AJ, Maiden MC, eds. (2001). Meningococcal Vaccines: Methods and Protocols. Totowa, NJ: Humana Press. ISBN 978-0-89603-801-1.
  8. Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Meningococcal Disease". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Centers for Disease Control and Prevention. Archived from the original on 2021-12-11. Retrieved 2021-01-31.
  9. Harrison LH (March 2010). "Epidemiological profile of meningococcal disease in the United States". Clinical Infectious Diseases. 50 Suppl 2 (Suppl 2): S37-44. doi:10.1086/648963. PMC 2820831. PMID 20144015.
  10. Griffiss JM, Schneider H, Mandrell RE, Yamasaki R, Jarvis GA, Kim JJ, et al. (1988). "Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane". Reviews of Infectious Diseases. 10 Suppl 2 (Suppl 2): S287-95. doi:10.1093/cid/10.supplement_2.s287. JSTOR 4454586. PMID 2460911.
  11. Jarrell KF, ed. (2009). Pili and Flagella: Current Research and Future Trends. Caister Academic Press. ISBN 978-1-904455-48-6.
  12. Ullrich M, ed. (2009). Bacterial Polysaccharides: Current Innovations and Future Trends. Caister Academic Press. ISBN 978-1-904455-45-5.
  13. Hill DJ, Griffiths NJ, Borodina E, Virji M (February 2010). "Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease". Clinical Science. 118 (9): 547–64. doi:10.1042/CS20090513. PMC 2830671. PMID 20132098.
  14. 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 Mola SJ, Nield LS, Weisse ME (2008). "Treatment and Prevention of N. meningitidis Infection". Infections in Medicine. 25 (3): 128–133. ISSN 0749-6524.
  15. McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, et al. (June 2013). "Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease". Microbiology and Molecular Biology Reviews. 77 (2): 234–52. doi:10.1128/MMBR.00056-12. PMC 3668674. PMID 23699256.
  16. 16.0 16.1 16.2 16.3 Piet JR, Huis in 't Veld RA, van Schaik BD, van Kampen AH, Baas F, van de Beek D, et al. (May 2011). "Genome sequence of Neisseria meningitidis serogroup B strain H44/76". Journal of Bacteriology. 193 (9): 2371–2. doi:10.1128/JB.01331-10. PMC 3133077. PMID 21378179.
  17. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. (March 2000). "Complete genome sequence of Neisseria meningitidis serogroup B strain MC58". Science. 287 (5459): 1809–15. Bibcode:2000Sci...287.1809.. doi:10.1126/science.287.5459.1809. JSTOR 3074600. PMID 10710307.
  18. Zhang Y, Yang J, Xu L, Zhu Y, Liu B, Shao Z, et al. (May 2014). "Complete Genome Sequence of Neisseria meningitidis Serogroup A Strain NMA510612, Isolated from a Patient with Bacterial Meningitis in China". Genome Announcements. 2 (3): e00360–14. doi:10.1128/genomeA.00360-14. PMC 4014685. PMID 24812217.
  19. Cehovin A, Simpson PJ, McDowell MA, Brown DR, Noschese R, Pallett M, et al. (February 2013). "Specific DNA recognition mediated by a type IV pilin". Proceedings of the National Academy of Sciences of the United States of America. 110 (8): 3065–70. Bibcode:2013PNAS..110.3065C. doi:10.1073/pnas.1218832110. PMC 3581936. PMID 23386723.
  20. Davidsen T, Rødland EA, Lagesen K, Seeberg E, Rognes T, Tønjum T (2004). "Biased distribution of DNA uptake sequences towards genome maintenance genes". Nucleic Acids Research. 32 (3): 1050–8. doi:10.1093/nar/gkh255. PMC 373393. PMID 14960717.
  21. Dyet K, Moir J (February 2006). "Effect of combined oxidative and nitrosative stress on Neisseria meningitidis". Biochemical Society Transactions. 34 (Pt 1): 197–9. doi:10.1042/BST0340197. PMID 16417521. S2CID 10045867.
  22. Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens". Infection, Genetics and Evolution. 8 (3): 267–85. CiteSeerX doi:10.1016/j.meegid.2008.01.002. PMID 18295550.
  23. 23.0 23.1 Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). New York: McGraw-Hill. pp. 329–333. ISBN 978-0-8385-8529-0.
  24. Riordan FA, Thomson AP, Ratcliffe JM, Sills JA, Diver MJ, Hart CA (October 1999). "Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: evidence of adrenal insufficiency?". Critical Care Medicine. 27 (10): 2257–61. doi:10.1097/00003246-199910000-00032. PMID 10548217.
  25. "Guidance for public health management of meningococcal disease in the UK" (pdf). Public Health England. 2019. GW-599. Archived from the original on 2020-12-31. Retrieved 2021-01-31.
  26. "Prevention". National Center for Immunization and Respiratory Diseases. Meningococcal Disease. Centers for Disease Control and Prevention. 31 May 2019. Archived from the original on 2020-10-30.
  27. 27.0 27.1 "Meningococcal Vaccination: What Everyone Should Know". National Center for Immunization and Respiratory Diseases. U.S. Centers for Disease Control and Prevention. 29 July 2019. Archived from the original on 2021-01-23.
  28. "FDA approves new combination vaccine that protects children against two bacterial diseases" (Press release). U.S. Food and Drug Administration. 14 June 2012. Archived from the original on 2017-01-19.{{cite press release}}: CS1 maint: unfit URL (link)
  29. "First vaccine approved by FDA to prevent serogroup B Meningococcal disease" (Press release). U.S. Food and Drug Administration. 29 October 2014. Archived from the original on 2021-01-22.
  30. Kelland K (9 January 2015). "Tailor-made vaccine set to banish Africa's meningitis epidemics". Reuters. Thompson Reuters. Archived from the original on 2019-12-18. Retrieved 31 January 2021.
  31. "Meningitis A nearly eliminated in Africa through vaccination, reaching more than 235 million people" (Press release). Ministerial Conference on Immunization in Africa. 22 February 2016. Archived from the original on 2017-02-02.
  32. 32.0 32.1 Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ (November 2004). "Practice guidelines for the management of bacterial meningitis". Clinical Infectious Diseases. 39 (9): 1267–84. doi:10.1086/425368. PMID 15494903.
  33. Valles J, Ferrer R, Fernández-Viladrich P (2005). "Bloodstream Infections Including Endocarditis and Meningitis". In van Saene HK, Silvestri L, de la Cal MA (eds.). Infection Control in the Intensive Care Unit (2nd ed.). Milan; New York: Springer. pp. 337–377. ISBN 88-470-0185-4.
  34. Coant PN, Kornberg AE, Duffy LC, Dryja DM, Hassan SM (August 1992). "Blood culture results as determinants in the organism identification of bacterial meningitis". Pediatric Emergency Care. 8 (4): 200–5. doi:10.1097/00006565-199208000-00006. PMID 1381091.
  35. Genco CA, Wetzler L, eds. (2010). Neisseria: Molecular Mechanisms of Pathogenesis. Caister Academic Press. ISBN 978-1-904455-51-6.
  36. Baarda BI, Sikora AE (2015). "Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease". Frontiers in Microbiology. 6: 1190. doi:10.3389/fmicb.2015.01190. PMC 4620152. PMID 26579097.
  37. 37.0 37.1 Stephens DS (June 2009). "Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis". Vaccine. 27 Suppl 2 (Suppl 2): B71-7. doi:10.1016/j.vaccine.2009.04.070. PMC 2712446. PMID 19477055.
  38. Manchanda V, Gupta S, Bhalla P (January 2006). "Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention". Indian Journal of Medical Microbiology. 24 (1): 7–19. doi:10.4103/0255-0857.19888. PMID 16505549.
  39. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson JA (2013). "Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis". PNAS. 110 (39): 15644–9. Bibcode:2013PNAS..11015644H. doi:10.1073/pnas.1313587110. PMC 3785731. PMID 23940360.
  40. Scheu AH, Lim SY, Metzner FJ, Mohammed S, Howarth M (2021). "NeissLock provides an inducible protein anhydride for covalent targeting of endogenous proteins". Nat. Commun. 12 (1): 717. Bibcode:2021NatCo..12..717S. doi:10.1038/s41467-021-20963-5. PMC 7846742. PMID 33514717.
  41. Spoerry C, Karlsson J, Aschtgen MS, Loh E (2021). "Neisseria meningitidis IgA1-specific serine protease exhibits novel cleavage activity against IgG3". Virulence. 12 (1): 389–403–9. doi:10.1080/21505594.2021.1871822. PMC 7834093. PMID 33459578.

External links